HIV 1 News and Research

RSS

Global Fund delays closing date for round 11 applications, says disbursements may not be available until 2013

The Global Fund to Fight HIV, TB and Malaria has delayed the closing date for applications for its next round of funding, reduced the estimated amount of money that will be available in that round, and potentially delayed the disbursement of the funds until 2013, PlusNews reports.

9 Nov 2011

Clinton expected to urge U.S., other countries to intensify HIV/AIDS prevention efforts in speech on Tuesday

In a speech to be delivered at the NIH, "Secretary of State Hillary Clinton is expected to call Tuesday for a new push by the U.S. and other countries to harness recent science to stem the HIV/AIDS pandemic," the Wall Street Journal reports.

9 Nov 2011

UC Santa Barbara's ImmuNet project focuses on targeted immunizations for infants, children

The University of California, Santa Barbara announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that address persistent health and development challenges. Professors Elizabeth Belding and Amr El Abbadi in the Computer Science Department will pursue an innovative global health research project, titled "ImmuNet: Targeted Immunizations for Infants and Children".

8 Nov 2011

Two decades since Magic Johnson’s HIV announcement

It is 20 years since basket ball legend Earvin ‘Magic’ Johnson, now 52 years-old, retired from the Lakers basketball team while announcing his diagnosis of HIV, a virus that causes AIDS.

8 Nov 2011

Children's Hospital project to investigate effectiveness of BET antagonists against HIV

Terri Finkel, M.D., Ph.D., chief of Rheumatology at Children's Hospital and Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, will pursue an innovative global health research project, titled "Use of a BET Antagonist to Control and Cure HIV Infection."

8 Nov 2011

St. Michael's project to develop vaccine that would eliminate latent HIV reservoirs

Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.

8 Nov 2011

Georgia Tech/CDC project focuses on microneedle patches for polio vaccination

Mark Prausnitz, Regents' professor in Georgia Tech's School of Chemical and Biomolecular Engineering, will pursue an innovative global health research project focused on using microneedle patches for the low-cost administration of polio vaccine through the skin in collaboration with researchers Steve Oberste and Mark Pallansch of the US Centers for Disease Control and Prevention.

8 Nov 2011

CRCHUM researcher receives Gates Foundation grant to eradicate HIV/AIDS

The Centre de recherche du Centre hospitalier de l'Universit- de Montr-al (CRCHUM) announced today that one of its researchers will receive funding of 100,000 US $ through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that address persistent health and development challenges.

7 Nov 2011

Electronic Nose can diagnose TB in symptomatic patients

A new hand-held device called the Electronic Nose, which has the potential to diagnose tuberculosis (TB) in symptomatic patients, was awarded a $950,000 grant from Grand Challenges Canada and the Bill & Melinda Gates Foundation today to support further development and testing of this ground-breaking technology.

7 Nov 2011

Encouraging results from SEEK's FLU-v Phase II study

SEEK, a leading UK privately-owned drug-discovery group, today announced encouraging results following the successful completion of its Universal Flu Vaccine Phase II challenge study.

7 Nov 2011

Study provides blueprint for design of new HIV drugs

Scientists have moved a step closer to understanding how one of our body's own proteins helps stop the human immunodeficiency virus (HIV-1) in its tracks.

7 Nov 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex Pharmaceuticals Incorporated today announced positive interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with chronic genotype 1 hepatitis C (HCV) and human immunodeficiency virus.

7 Nov 2011

Abbott wins 2011 Scrip Award for Corporate Social Responsibility

Scrip, a leading global pharmaceutical and biotech news organisation, honored Abbott and its philanthropic foundation, the Abbott Fund, with a 2011 Scrip Award for Corporate Social Responsibility (CSR) at Scrip's seventh annual awards ceremony in London on Thursday evening.

5 Nov 2011

Guardian profiles Anglo American CMO's efforts to fight HIV/AIDS

The Guardian profiles Brian Brink, chief medical officer at Anglo American, South Africa's largest private-sector employer, and the company's efforts to treat and prevent HIV among its employees.

5 Nov 2011

HIV and AIDS do not discriminate

They don't discriminate. They can affect the young, older adults and pregnant women. They also strike rich and poor, male and female. People from all walks of life can become infected with HIV and AIDS. Knowing how to prevent them, how to live with them, and the strides made over the years to fight them are essential. This knowledge is one of the main goals of World AIDS Day, which is observed on December 1 each year.

5 Nov 2011

Misconceptions affecting participation in HIV vaccine trials

On December 1st, World AIDS Day 2011 will be observed in many countries around the globe. The theme of this year's World AIDS Day is "Getting to Zero"—specifically, zero new HIV infections, zero discrimination and zero AIDS-related deaths.

5 Nov 2011

Vertex announces 16 grant recipients of Hep-C Circle of Care program

Vertex Pharmaceuticals Incorporated today announced that it has awarded 16 grants totaling approximately $1.5 million to a variety of academic, patient and community groups as part of the Vertex Hep-C Circle of Care program, a pilot competitive grants program designed to foster innovative approaches to patient care and support people living with chronic hepatitis C.

5 Nov 2011

Ansell launches GAMMEX Powder-Free glove with AMT Antimicrobial Technology in Europe

Global leader in healthcare protection and safety solutions lands CE Mark for GAMMEX Powder-Free Gloves with AMT Antimicrobial Technology.

5 Nov 2011

Kenyan company receives WHO prequalification for generic ARV

"The cost of HIV/AIDS medicine is expected to drop by 30 percent in Kenya, enabling more people to access life-prolonging drugs, after the World Health Organization (WHO) gave the green light to a local company manufacturing generics, The Star newspaper reported on Wednesday," AlertNet reports.

4 Nov 2011

Investment in USAID has saved millions of lives, is critical for U.S. security

In this Politico opinion piece, Brian Atwood and colleagues, all former USAID administrators in previous Democratic or Republican administrations and current advisers to the U.S. Global Leadership Coalition, write, "Over the last half-century, USAID has had an extraordinary record of accomplishment. Using less than one percent of the U.S. budget annually, the American people have demonstrated their deepest values through USAID programs, saving tens of millions of lives worldwide with immunization programs, oral rehydration therapy, treatment for HIV/AIDS and work on other diseases."

4 Nov 2011